A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006)

Completed · Phase 1

Conditions studied: Healthy

In brief

The goal of this study this study is to learn about the safety of MK-1167 and if people tolerate it. Researchers will compare what happens to MK-1167 in the body when it is given with and without another medicine called diltiazem.

Key facts

Study ID

NCT06703463

Run by

Merck Sharp & Dohme LLC

People needed

16

Starts

2023-10-17

Expected to finish

2024-02-02

Last updated by the study team

2024-11-25

Who can join

Age: 19 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The main inclusion criteria include but are not limited to the following:
• Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting
• Body mass index (BMI) ≥18.0 and ≤32.0 kg/m\^2
• Able to swallow multiple capsules
• In good health

You may not qualify if…

• The main exclusion criteria include but are not limited to the following:
• History or presence of second- or third-degree atrioventricular heart block (except in participants with a functional artificial pacemaker)
• History or presence of clinically significant sick sinus syndrome
• History of cancer (malignancy) within the past 5 years
• Unable to refrain from or anticipates the use of any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing

Where it is running

• Celerion (Site 0002) — Lincoln, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.